Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.79 |
Intermediate Similarity |
NPD8035 |
Phase 2 |
0.79 |
Intermediate Similarity |
NPD8034 |
Phase 2 |
0.787 |
Intermediate Similarity |
NPD6881 |
Approved |
0.787 |
Intermediate Similarity |
NPD6899 |
Approved |
0.785 |
Intermediate Similarity |
NPD5739 |
Approved |
0.785 |
Intermediate Similarity |
NPD6675 |
Approved |
0.785 |
Intermediate Similarity |
NPD7128 |
Approved |
0.785 |
Intermediate Similarity |
NPD6402 |
Approved |
0.7835 |
Intermediate Similarity |
NPD7520 |
Clinical (unspecified phase) |
0.7818 |
Intermediate Similarity |
NPD6649 |
Approved |
0.7818 |
Intermediate Similarity |
NPD6650 |
Approved |
0.7798 |
Intermediate Similarity |
NPD6373 |
Approved |
0.7798 |
Intermediate Similarity |
NPD6372 |
Approved |
0.7778 |
Intermediate Similarity |
NPD5697 |
Approved |
0.7739 |
Intermediate Similarity |
NPD6319 |
Approved |
0.7727 |
Intermediate Similarity |
NPD7290 |
Approved |
0.7727 |
Intermediate Similarity |
NPD6883 |
Approved |
0.7727 |
Intermediate Similarity |
NPD7102 |
Approved |
0.7706 |
Intermediate Similarity |
NPD7320 |
Approved |
0.7706 |
Intermediate Similarity |
NPD5345 |
Clinical (unspecified phase) |
0.7685 |
Intermediate Similarity |
NPD6008 |
Approved |
0.7658 |
Intermediate Similarity |
NPD6869 |
Approved |
0.7658 |
Intermediate Similarity |
NPD6847 |
Approved |
0.7658 |
Intermediate Similarity |
NPD8130 |
Phase 1 |
0.7658 |
Intermediate Similarity |
NPD6617 |
Approved |
0.7647 |
Intermediate Similarity |
NPD6399 |
Phase 3 |
0.7636 |
Intermediate Similarity |
NPD6012 |
Approved |
0.7636 |
Intermediate Similarity |
NPD6014 |
Approved |
0.7636 |
Intermediate Similarity |
NPD6013 |
Approved |
0.7627 |
Intermediate Similarity |
NPD7492 |
Approved |
0.7619 |
Intermediate Similarity |
NPD7638 |
Approved |
0.7615 |
Intermediate Similarity |
NPD5701 |
Approved |
0.7589 |
Intermediate Similarity |
NPD8297 |
Approved |
0.7589 |
Intermediate Similarity |
NPD6882 |
Approved |
0.7586 |
Intermediate Similarity |
NPD6054 |
Approved |
0.7583 |
Intermediate Similarity |
NPD7736 |
Approved |
0.7563 |
Intermediate Similarity |
NPD6616 |
Approved |
0.7549 |
Intermediate Similarity |
NPD6079 |
Approved |
0.7547 |
Intermediate Similarity |
NPD7639 |
Approved |
0.7547 |
Intermediate Similarity |
NPD7640 |
Approved |
0.7545 |
Intermediate Similarity |
NPD6011 |
Approved |
0.7525 |
Intermediate Similarity |
NPD5328 |
Approved |
0.7522 |
Intermediate Similarity |
NPD4632 |
Approved |
0.75 |
Intermediate Similarity |
NPD7078 |
Approved |
0.7478 |
Intermediate Similarity |
NPD7115 |
Discovery |
0.7474 |
Intermediate Similarity |
NPD6697 |
Approved |
0.7474 |
Intermediate Similarity |
NPD6115 |
Approved |
0.7474 |
Intermediate Similarity |
NPD6118 |
Approved |
0.7474 |
Intermediate Similarity |
NPD6114 |
Approved |
0.7458 |
Intermediate Similarity |
NPD6370 |
Approved |
0.7449 |
Intermediate Similarity |
NPD4788 |
Approved |
0.7436 |
Intermediate Similarity |
NPD6059 |
Approved |
0.7411 |
Intermediate Similarity |
NPD4634 |
Approved |
0.7404 |
Intermediate Similarity |
NPD7748 |
Approved |
0.7383 |
Intermediate Similarity |
NPD5286 |
Approved |
0.7383 |
Intermediate Similarity |
NPD5285 |
Approved |
0.7383 |
Intermediate Similarity |
NPD4696 |
Approved |
0.7379 |
Intermediate Similarity |
NPD7515 |
Phase 2 |
0.7377 |
Intermediate Similarity |
NPD7319 |
Approved |
0.7373 |
Intermediate Similarity |
NPD6015 |
Approved |
0.7373 |
Intermediate Similarity |
NPD6016 |
Approved |
0.7358 |
Intermediate Similarity |
NPD6083 |
Phase 2 |
0.7358 |
Intermediate Similarity |
NPD4755 |
Approved |
0.7358 |
Intermediate Similarity |
NPD6084 |
Phase 2 |
0.7358 |
Intermediate Similarity |
NPD7902 |
Approved |
0.7355 |
Intermediate Similarity |
NPD8293 |
Discontinued |
0.7345 |
Intermediate Similarity |
NPD6401 |
Clinical (unspecified phase) |
0.7328 |
Intermediate Similarity |
NPD6009 |
Approved |
0.7311 |
Intermediate Similarity |
NPD5988 |
Approved |
0.7264 |
Intermediate Similarity |
NPD5222 |
Approved |
0.7264 |
Intermediate Similarity |
NPD5220 |
Clinical (unspecified phase) |
0.7264 |
Intermediate Similarity |
NPD4697 |
Phase 3 |
0.7264 |
Intermediate Similarity |
NPD5221 |
Approved |
0.7263 |
Intermediate Similarity |
NPD6117 |
Approved |
0.725 |
Intermediate Similarity |
NPD8328 |
Phase 3 |
0.725 |
Intermediate Similarity |
NPD7604 |
Phase 2 |
0.7248 |
Intermediate Similarity |
NPD5226 |
Approved |
0.7248 |
Intermediate Similarity |
NPD5224 |
Approved |
0.7248 |
Intermediate Similarity |
NPD5211 |
Phase 2 |
0.7248 |
Intermediate Similarity |
NPD5225 |
Approved |
0.7248 |
Intermediate Similarity |
NPD4633 |
Approved |
0.7241 |
Intermediate Similarity |
NPD6274 |
Approved |
0.7228 |
Intermediate Similarity |
NPD3618 |
Phase 1 |
0.7227 |
Intermediate Similarity |
NPD5983 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD4700 |
Approved |
0.7212 |
Intermediate Similarity |
NPD6411 |
Approved |
0.7203 |
Intermediate Similarity |
NPD7101 |
Approved |
0.7203 |
Intermediate Similarity |
NPD7100 |
Approved |
0.72 |
Intermediate Similarity |
NPD4786 |
Approved |
0.7196 |
Intermediate Similarity |
NPD5173 |
Approved |
0.7188 |
Intermediate Similarity |
NPD6116 |
Phase 1 |
0.7182 |
Intermediate Similarity |
NPD5174 |
Approved |
0.7182 |
Intermediate Similarity |
NPD5175 |
Approved |
0.7179 |
Intermediate Similarity |
NPD8295 |
Clinical (unspecified phase) |
0.7158 |
Intermediate Similarity |
NPD3703 |
Phase 2 |
0.7156 |
Intermediate Similarity |
NPD5223 |
Approved |
0.7131 |
Intermediate Similarity |
NPD7507 |
Approved |
0.7131 |
Intermediate Similarity |
NPD6336 |
Discontinued |
0.713 |
Intermediate Similarity |
NPD4225 |
Approved |
0.713 |
Intermediate Similarity |
NPD5696 |
Approved |
0.7119 |
Intermediate Similarity |
NPD6335 |
Approved |
0.7117 |
Intermediate Similarity |
NPD5141 |
Approved |
0.7094 |
Intermediate Similarity |
NPD6868 |
Approved |
0.7091 |
Intermediate Similarity |
NPD7632 |
Discontinued |
0.7087 |
Intermediate Similarity |
NPD7513 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD7901 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD7900 |
Approved |
0.7069 |
Intermediate Similarity |
NPD8133 |
Approved |
0.7059 |
Intermediate Similarity |
NPD3574 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD7521 |
Approved |
0.7059 |
Intermediate Similarity |
NPD7334 |
Approved |
0.7059 |
Intermediate Similarity |
NPD6684 |
Approved |
0.7059 |
Intermediate Similarity |
NPD5330 |
Approved |
0.7059 |
Intermediate Similarity |
NPD6409 |
Approved |
0.7059 |
Intermediate Similarity |
NPD7146 |
Approved |
0.7053 |
Intermediate Similarity |
NPD6113 |
Clinical (unspecified phase) |
0.7048 |
Intermediate Similarity |
NPD7637 |
Suspended |
0.7034 |
Intermediate Similarity |
NPD6317 |
Approved |
0.7019 |
Intermediate Similarity |
NPD5764 |
Clinical (unspecified phase) |
0.7019 |
Intermediate Similarity |
NPD6101 |
Approved |
0.7009 |
Intermediate Similarity |
NPD6356 |
Clinical (unspecified phase) |
0.7009 |
Intermediate Similarity |
NPD5695 |
Phase 3 |
0.7 |
Intermediate Similarity |
NPD3667 |
Approved |
0.6991 |
Remote Similarity |
NPD6412 |
Phase 2 |
0.6981 |
Remote Similarity |
NPD5778 |
Approved |
0.6981 |
Remote Similarity |
NPD4202 |
Approved |
0.6981 |
Remote Similarity |
NPD5779 |
Approved |
0.6975 |
Remote Similarity |
NPD6314 |
Approved |
0.6975 |
Remote Similarity |
NPD6313 |
Approved |
0.6942 |
Remote Similarity |
NPD6908 |
Approved |
0.6942 |
Remote Similarity |
NPD6909 |
Approved |
0.6942 |
Remote Similarity |
NPD6921 |
Approved |
0.6942 |
Remote Similarity |
NPD6291 |
Clinical (unspecified phase) |
0.693 |
Remote Similarity |
NPD4729 |
Approved |
0.693 |
Remote Similarity |
NPD5128 |
Approved |
0.693 |
Remote Similarity |
NPD4730 |
Approved |
0.6923 |
Remote Similarity |
NPD6672 |
Approved |
0.6923 |
Remote Similarity |
NPD6903 |
Approved |
0.6923 |
Remote Similarity |
NPD5737 |
Approved |
0.6903 |
Remote Similarity |
NPD4767 |
Approved |
0.6903 |
Remote Similarity |
NPD4768 |
Approved |
0.688 |
Remote Similarity |
NPD6033 |
Approved |
0.6875 |
Remote Similarity |
NPD4754 |
Approved |
0.687 |
Remote Similarity |
NPD4061 |
Clinical (unspecified phase) |
0.687 |
Remote Similarity |
NPD8132 |
Clinical (unspecified phase) |
0.6863 |
Remote Similarity |
NPD3665 |
Phase 1 |
0.6863 |
Remote Similarity |
NPD3133 |
Approved |
0.6863 |
Remote Similarity |
NPD3666 |
Approved |
0.6857 |
Remote Similarity |
NPD4753 |
Phase 2 |
0.6852 |
Remote Similarity |
NPD5210 |
Approved |
0.6852 |
Remote Similarity |
NPD4629 |
Approved |
0.6842 |
Remote Similarity |
NPD4808 |
Clinical (unspecified phase) |
0.6842 |
Remote Similarity |
NPD4809 |
Clinical (unspecified phase) |
0.6838 |
Remote Similarity |
NPD6053 |
Discontinued |
0.6827 |
Remote Similarity |
NPD3573 |
Approved |
0.681 |
Remote Similarity |
NPD5250 |
Approved |
0.681 |
Remote Similarity |
NPD5251 |
Approved |
0.681 |
Remote Similarity |
NPD5248 |
Approved |
0.681 |
Remote Similarity |
NPD5249 |
Phase 3 |
0.681 |
Remote Similarity |
NPD5955 |
Clinical (unspecified phase) |
0.681 |
Remote Similarity |
NPD5247 |
Approved |
0.6783 |
Remote Similarity |
NPD6686 |
Approved |
0.6752 |
Remote Similarity |
NPD5217 |
Approved |
0.6752 |
Remote Similarity |
NPD5216 |
Approved |
0.6752 |
Remote Similarity |
NPD5215 |
Approved |
0.6698 |
Remote Similarity |
NPD6080 |
Approved |
0.6698 |
Remote Similarity |
NPD6673 |
Approved |
0.6698 |
Remote Similarity |
NPD6904 |
Approved |
0.6697 |
Remote Similarity |
NPD1698 |
Clinical (unspecified phase) |
0.6696 |
Remote Similarity |
NPD1700 |
Approved |
0.6694 |
Remote Similarity |
NPD7327 |
Approved |
0.6694 |
Remote Similarity |
NPD7328 |
Approved |
0.6667 |
Remote Similarity |
NPD5169 |
Approved |
0.6667 |
Remote Similarity |
NPD6334 |
Approved |
0.6667 |
Remote Similarity |
NPD5135 |
Approved |
0.6667 |
Remote Similarity |
NPD5777 |
Approved |
0.6667 |
Remote Similarity |
NPD8170 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD5134 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD6333 |
Approved |
0.6667 |
Remote Similarity |
NPD6371 |
Approved |
0.6639 |
Remote Similarity |
NPD7516 |
Approved |
0.6638 |
Remote Similarity |
NPD5168 |
Approved |
0.6636 |
Remote Similarity |
NPD5785 |
Approved |
0.6634 |
Remote Similarity |
NPD7525 |
Registered |
0.6633 |
Remote Similarity |
NPD3702 |
Approved |
0.6632 |
Remote Similarity |
NPD3699 |
Clinical (unspecified phase) |
0.6632 |
Remote Similarity |
NPD3700 |
Clinical (unspecified phase) |
0.661 |
Remote Similarity |
NPD5127 |
Approved |
0.6606 |
Remote Similarity |
NPD6001 |
Approved |
0.6574 |
Remote Similarity |
NPD5281 |
Approved |
0.6574 |
Remote Similarity |
NPD5284 |
Approved |
0.6571 |
Remote Similarity |
NPD6098 |
Approved |
0.6571 |
Remote Similarity |
NPD5786 |
Approved |
0.6569 |
Remote Similarity |
NPD5369 |
Approved |
0.6562 |
Remote Similarity |
NPD4245 |
Approved |
0.6562 |
Remote Similarity |
NPD4244 |
Approved |
0.6552 |
Remote Similarity |
NPD5954 |
Clinical (unspecified phase) |
0.6538 |
Remote Similarity |
NPD3668 |
Phase 3 |
0.6532 |
Remote Similarity |
NPD8379 |
Approved |
0.6532
|
Remote Similarity |
NPD8378 |
Approved |